The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

To assess the potential clinical utility of cell-free DNA (cfDNA)-based biomarkers for identifying gastric cancer (GC) patients who benefit from nivolumab. From 31 GC patients treated with nivolumab monotherapy (240 mg/body, Bi-weekly) in 3rd or later line setting, we prospectively collected blood s...

Descripción completa

Detalles Bibliográficos
Autores principales: Inagaki, Chiaki, Kawakami, Hisato, Maeda, Daichi, Sakai, Daisuke, Urakawa, Shinya, Nishida, Kentaro, Kudo, Toshihiro, Doki, Yuichiro, Eguchi, Hidetoshi, Wada, Hisashi, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079661/
https://www.ncbi.nlm.nih.gov/pubmed/37024664
http://dx.doi.org/10.1038/s41598-023-32645-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079661/
https://www.ncbi.nlm.nih.gov/pubmed/37024664
http://dx.doi.org/10.1038/s41598-023-32645-x

Ejemplares similares